19 research outputs found
Clinical aspects of determining the state of platelet function
The article is devoted to clinical aspects of platelet function determination in clinical practice. The review provides recent data of some major research and registers in patients with different forms of ischemic heart disease after PCI during double antiplatelet therapy. The existence of ' therapeutic window β problem between ischemic and bleeding complications during antiplatelet therapy is revealed.Π‘ΡΠ°ΡΡΡ ΠΏΠΎΡΠ²ΡΡΠ΅Π½Π° ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌ Π°ΡΠΏΠ΅ΠΊΡΠ°ΠΌ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ ΡΠΎΡΡΠΎΡΠ½ΠΈΡ ΡΡΠ½ΠΊΡΠΈΠΈ ΡΡΠΎΠΌΠ±ΠΎΡΠΈΡΠΎΠ² Π² ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΏΡΠ°ΠΊΡΠΈΠΊΠ΅. Π ΠΎΠ±Π·ΠΎΡΠ΅ ΠΏΡΠΈΠ²ΠΎΠ΄ΡΡΡΡ Π΄Π°Π½Π½ΡΠ΅ ΠΏΠΎΡΠ»Π΅Π΄Π½ΠΈΡ
ΠΊΡΡΠΏΠ½ΡΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ ΠΈ ΡΠ΅Π³ΠΈΡΡΡΠΎΠ², ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠΌΡΡ
Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΡΠ°Π·Π»ΠΈΡΠ½ΡΠΌΠΈ ΡΠΎΡΠΌΠ°ΠΌΠΈ ΠΠΠ‘ ΠΏΠΎΡΠ»Π΅ Π§ΠΠ Π½Π° ΡΠΎΠ½Π΅ Π΄Π²ΠΎΠΉΠ½ΠΎΠΉ Π°Π½ΡΠΈΡΡΠΎΠΌΠ±ΠΎΡΠΈΡΠ°ΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ. ΠΡΡΠ²Π»ΡΠ΅ΡΡΡ ΠΏΡΠΎΠ±Π»Π΅ΠΌΠ° ΡΡΡΠ΅ΡΡΠ²ΠΎΠ²Π°Π½ΠΈΡ Β«ΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΎΠΊΠ½Π°Β» ΠΌΠ΅ΠΆΠ΄Ρ ΠΈΡΠ΅ΠΌΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ ΠΈ Π³Π΅ΠΌΠΎΡΡΠ°Π³ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΡΠΌΠΈ ΠΏΡΠΈ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π°Π½ΡΠΈΠ°Π³ΡΠ΅Π³Π°Π½ΡΠ°ΠΌΠΈ
Application differentiated approach in determination of risk stratification in patients with nste acs in different prognostic models
Prognostic model GRACE was ineffective in prognosis of lethal cases and combination of unfavourable cardiovascular events - death and myocardial infarction during in-hospital period. During 6 months of observation this model showed middle level of prognostic significance. Prognostic model TIMI showed the same results regarding prediction of combined point β death, myocardial infarction, refractory ischemia during 14 days of in-hospital period and 1-year observation. Prognostic model PURSUIT showed high level of prognostic power during 30-days and annual observation. Comparing GRACE and PURSUIT in relation to death from all reasons and combined point death/myocardial infarction during 12 months of observation it was revealed that model PURSUIT had more accurate estimation.ΠΡΠΎΠ³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠ°Ρ ΡΠΊΠ°Π»Π° GRACE ΠΎΠΊΠ°Π·Π°Π»Π°ΡΡ Π½Π΅ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠΉ Π² ΠΏΡΠΎΠ³Π½ΠΎΠ·ΠΈΡΠΎΠ²Π°Π½ΠΈΠΈ ΡΠ»ΡΡΠ°Π΅Π² ΡΠΌΠ΅ΡΡΠΈ ΠΈ ΡΠΎΠ²ΠΎΠΊΡΠΏΠ½ΠΎΡΡΠΈ ΡΠ»ΡΡΠ°Π΅Π² ΡΠΌΠ΅ΡΡΠΈ/ΠΠ Π² ΠΏΠ΅ΡΠΈΠΎΠ΄ Π³ΠΎΡΠΏΠΈΡΠ°Π»ΠΈΠ·Π°ΡΠΈΠΈ. ΠΠ° ΠΏΠ΅ΡΠΈΠΎΠ΄ 6-ΠΌΠ΅ΡΡΡΠ½ΠΎΠ³ΠΎ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ ΡΠΊΠ°Π»Π° ΠΏΡΠΎΠ΄Π΅ΠΌΠΎΠ½ΡΡΡΠΈΡΠΎΠ²Π°Π»Π° ΡΡΠ΅Π΄Π½ΠΈΠΉ ΡΡΠΎΠ²Π΅Π½Ρ ΠΏΡΠΎΠ³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π·Π½Π°ΡΠΈΠΌΠΎΡΡΠΈ. Π‘Ρ
ΠΎΠ΄Π½ΡΠ΅ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ Π±ΡΠ»ΠΈ Π²ΡΡΠ²Π»Π΅Π½Ρ ΠΈ Ρ ΠΌΠΎΠ΄Π΅Π»ΠΈ TIMI Π² ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠΈ ΠΏΡΠ΅Π΄ΡΠΊΠ°Π·Π°Π½ΠΈΡ ΡΠΌΠ΅ΡΡΠΈ/ ΠΠ/ΡΠ΅ΡΡΠ°ΠΊΡΠ΅ΡΠ½ΠΎΠΉ ΠΈΡΠ΅ΠΌΠΈΠΈ Π½Π° ΠΏΠ΅ΡΠΈΠΎΠ΄ 14-Π΄Π½Π΅Π²Π½ΠΎΠ³ΠΎ ΠΈ Π³ΠΎΠ΄ΠΎΠ²ΠΎΠ³ΠΎ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ. ΠΠΎΠ΄Π΅Π»Ρ ΡΠΈΡΠΊΠ° PURSUIT ΠΏΠΎΠΊΠ°Π·Π°Π»Π° ΠΎΡΠ΅Π½Ρ Ρ
ΠΎΡΠΎΡΠΈΠΉ ΡΡΠΎΠ²Π΅Π½Ρ ΠΏΡΠΎΠ³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π·Π½Π°ΡΠΈΠΌΠΎΡΡΠΈ Π½Π° ΠΏΠ΅ΡΠΈΠΎΠ΄ 30-Π΄Π½Π΅Π²Π½ΠΎΠ³ΠΎ ΠΈ Π³ΠΎΠ΄ΠΎΠ²ΠΎΠ³ΠΎ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ. ΠΡΠΈ ΡΡΠ°Π²Π½Π΅Π½ΠΈΠΈ ΠΌΠΎΠ΄Π΅Π»Π΅ΠΉ GRACE ΠΈ PURSUIT Π² ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠΈ ΡΠΌΠ΅ΡΡΠΈ ΠΎΡ Π²ΡΠ΅Ρ
ΠΏΡΠΈΡΠΈΠ½ ΠΈ ΡΠΎΠ²ΠΎΠΊΡΠΏΠ½ΠΎΡΡΠΈ ΡΠΌΠ΅ΡΡΠΈ/ΠΠ Π½Π° ΠΏΠ΅ΡΠΈΠΎΠ΄ 12-ΠΌΠ΅ΡΡΡΠ½ΠΎΠ³ΠΎ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ Π²ΡΡΠ²Π»Π΅Π½ΠΎ, ΡΡΠΎ ΠΏΡΠΎΠ³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠ°Ρ ΡΠΎΡΠ½ΠΎΡΡΡ ΠΎΡΠ΅Π½ΠΎΠΊ Π»ΡΡΡΠ΅ Ρ ΡΠΊΠ°Π»Ρ PURSUIT
Comparative estimation of prognostic value of the models GRACE, TIMI, PURSUIT in risk stratification of coronary complications in patients with non-ST-elevation acute coronary syndrome
The aim of investigation was to held comparative analysis of prognostic value of different models of short-term and long-term cardiovascular risk estimation in patients with non-ST-elevation acute coronary syndrome (ACS). Material and methods. This prospective investigation included 150 patients with non-ST-elevation ACS. During observation estimation of risk complications development level was held with the help of prognostic models GRACE, TIMI, PURSUIT, comparative analysis of predictive possibilities of this models, was held. Results. According to the results of investigation model GRACE demonstrated the most high sensitivity (100%) in prediction of all cause mortality during in-hospital observation. The most high specificity (90%) was marked in prediction of unfavourable outcomes during 6-months observation. TIMI risk stratification model revealed the most high sensitivity (64%), specificity (77%) and predictive accuracy (67%) in prediction of death/myocardial infarction/ischemia during 1-year observation, showed maximal value of positive predictive accuracy during in-hospital period and 12 months of observation in compare with other models. PURSUIT model of cardiovascular risk estimation showed the highest specificity (91%), which was marked in prediction of death/myocardial infarction during next 12 months. High predictive accuracy of this model (91 %) related to death/myocardial infarction revealed during 6 months and was maintained during 1-year observation. Conclusion. All systems of risk stratification had high prognostic value, negative predictive accuracy, that is all of them were effective in prognosis of favourable events in patients with non-ST-elevation ACS. GRACE model of risk stratification had maximal sensitivity in prediction of death and death or myocardial infarction during hospitalization and 6-month or 1 -year dynamic observation. System of risk stratification TIMI showed maximal value of positive predictive accuracy during in-hospital period and dynamic observation. System of risk stratification PURSUIT demonstrated maximal specificity in prediction of in-hospital, 6-month and 1-year outcomes. Also this model had maximal predictive accuracy related to the prognosis of death and death/myocardial infarction during in-hospital period and 1-year observation.Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ: ΠΏΡΠΎΠ²Π΅ΡΡΠΈ ΡΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· ΠΏΡΠΎΠ³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ΅Π½Π½ΠΎΡΡΠΈ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
ΠΌΠΎΠ΄Π΅Π»Π΅ΠΉ ΠΎΡΠ΅Π½ΠΊΠΈ ΠΊΡΠ°ΡΠΊΠΎΡΡΠΎΡΠ½ΠΎΠ³ΠΎ ΠΈ Π΄ΠΎΠ»Π³ΠΎΡΡΠΎΡΠ½ΠΎΠ³ΠΎ ΠΊΠΎΡΠΎΠ½Π°ΡΠ½ΠΎΠ³ΠΎ ΡΠΈΡΠΊΠ° Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΎΡΡΡΡΠΌ ΠΊΠΎΡΠΎΠ½Π°ΡΠ½ΡΠΌ ΡΠΈΠ½Π΄ΡΠΎΠΌΠΎΠΌ Π±Π΅Π· ΡΡΠΎΠΉΠΊΠΈΡ
ΠΏΠΎΠ΄ΡΠ΅ΠΌΠΎΠ² ΡΠ΅Π³ΠΌΠ΅Π½ΡΠ° ST. ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π ΠΏΡΠΎΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠ΅ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΠ΅ Π²ΠΊΠ»ΡΡΠ΅Π½ΠΎ 150 Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΎΡΡΡΡΠΌ ΠΊΠΎΡΠΎΠ½Π°ΡΠ½ΡΠΌ ΡΠΈΠ½Π΄ΡΠΎΠΌΠΎΠΌ Π±Π΅Π· ΡΡΠΎΠΉΠΊΠΈΡ
ΠΏΠΎΠ΄ΡΠ΅ΠΌΠΎΠ² ΡΠ΅Π³ΠΌΠ΅Π½ΡΠ° ST (ΠΠΠ‘ΠΠΠΠ’). Π Ρ
ΠΎΠ΄Π΅ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»Π°ΡΡ ΠΎΡΠ΅Π½ΠΊΠ° ΡΡΠΎΠ²Π½Ρ ΡΠΈΡΠΊΠ° ΡΠ°Π·Π²ΠΈΡΠΈΡ ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ Ρ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ΠΌ ΠΏΡΠΎΠ³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΌΠΎΠ΄Π΅Π»Π΅ΠΉ GRACE, TIMI, PURSUIT; ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΡΡ ΡΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· ΠΏΡΠ΅Π΄ΠΈΠΊΡΠΈΠ²Π½ΡΡ
Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΠ΅ΠΉ ΠΈΡΠΏΠΎΠ»ΡΠ·ΡΠ΅ΠΌΡΡ
ΠΌΠΎΠ΄Π΅Π»Π΅ΠΉ. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π‘ΠΎΠ³Π»Π°ΡΠ½ΠΎ ΠΏΠΎΠ»ΡΡΠ΅Π½Π½ΡΠΌ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠ°ΠΌ Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ Π²ΡΡΠΎΠΊΠ°Ρ ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡ ΠΌΠΎΠ΄Π΅Π»ΠΈ GRACE (100%) ΠΎΡΠΌΠ΅ΡΠ°Π»Π°ΡΡ Π² ΠΏΡΠ΅Π΄ΡΠΊΠ°Π·Π°Π½ΠΈΠΈ ΡΠΌΠ΅ΡΡΠΈ ΠΎΡ Π²ΡΠ΅Ρ
ΠΏΡΠΈΡΠΈΠ½ Π² Π³ΠΎΡΠΏΠΈΡΠ°Π»ΡΠ½ΡΠΉ ΠΏΠ΅ΡΠΈΠΎΠ΄. ΠΠ°ΠΈΠ±ΠΎΠ»Π΅Π΅ Π²ΡΡΠΎΠΊΠ°Ρ ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ½ΠΎΡΡΡ (90%) ΠΎΡΠΌΠ΅ΡΠ°Π»Π°ΡΡ Π² ΠΏΡΠΎΠ³Π½ΠΎΠ·ΠΈΡΠΎΠ²Π°Π½ΠΈΠΈ Π»Π΅ΡΠ°Π»ΡΠ½ΡΡ
ΠΈΡΡ
ΠΎΠ΄ΠΎΠ² Π² ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ 6-ΠΌΠ΅ΡΡΡΠ½ΠΎΠ³ΠΎ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ. Π‘ΠΈΡΡΠ΅ΠΌΠ° ΡΠΈΡΠΊ-ΡΡΡΠ°ΡΠΈΡΠΈΠΊΠ°ΡΠΈΠΈ TIMI ΠΏΡΠΎΠ΄Π΅ΠΌΠΎΠ½ΡΡΡΠΈΡΠΎΠ²Π°Π»Π° Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ Π²ΡΡΠΎΠΊΠΈΠ΅ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΠΈ (64%), ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ½ΠΎΡΡΠΈ (77%) ΠΈ ΠΏΡΠ΅Π΄ΠΈΠΊΡΠΈΠ²Π½ΠΎΠΉ ΡΠΎΡΠ½ΠΎΡΡΠΈ (67%) Π² ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠΈ ΠΏΡΠ΅Π΄ΡΠΊΠ°Π·Π°Π½ΠΈΡ ΡΠΌΠ΅ΡΡΠΈ/ΠΠ/ΠΈΡΠ΅ΠΌΠΈΠΈ Π½Π° ΠΏΠ΅ΡΠΈΠΎΠ΄ Π³ΠΎΠ΄ΠΎΠ²ΠΎΠ³ΠΎ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ; ΠΏΠΎΠΊΠ°Π·Π°Π»Π° Π½Π°ΠΈΠ±ΠΎΠ»ΡΡΠ΅Π΅ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ (ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ Π΄ΡΡΠ³ΠΈΠΌΠΈ ΡΠΊΠ°Π»Π°ΠΌΠΈ) ΠΏΠΎΠ»ΠΎΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΏΡΠ΅Π΄ΡΠΊΠ°Π·ΡΡΡΠ΅ΠΉ ΡΠΎΡΠ½ΠΎΡΡΠΈ ΠΈ Π² ΠΏΠ΅ΡΠΈΠΎΠ΄ Π³ΠΎΡΠΏΠΈΡΠ°Π»ΠΈΠ·Π°ΡΠΈΠΈ, ΠΈ Π² ΠΏΠ΅ΡΠΈΠΎΠ΄ 12-ΠΌΠ΅ΡΡΡΠ½ΠΎΠ³ΠΎ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ. Π‘ΠΈΡΡΠ΅ΠΌΠ° ΠΎΡΠ΅Π½ΠΊΠΈ ΡΠΈΡΠΊΠ° PURSUIT ΠΏΠΎΠΊΠ°Π·Π°Π»Π° Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ Π²ΡΡΠΎΠΊΡΡ ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ½ΠΎΡΡΡ (91 %), ΠΊΠΎΡΠΎΡΠ°Ρ Π½Π°Π±Π»ΡΠ΄Π°Π»Π°ΡΡ Π² ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠΈ ΠΏΡΠΎΠ³Π½ΠΎΠ·ΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΡΠΌΠ΅ΡΡΠΈ/ΠΠ Π² ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ ΠΏΠΎΡΠ»Π΅Π΄ΡΡΡΠΈΡ
12 ΠΌΠ΅ΡΡΡΠ΅Π². ΠΡΡΠΎΠΊΠ°Ρ ΠΏΡΠ΅Π΄ΠΈΠΊΡΠΈΠ²Π½Π°Ρ ΡΠΎΡΠ½ΠΎΡΡΡ Π΄Π°Π½Π½ΠΎΠΉ ΠΌΠΎΠ΄Π΅Π»ΠΈ (91%) Π² ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠΈ ΡΠΌΠ΅ΡΡΠΈ/ΠΠ ΠΎΡΠΌΠ΅ΡΠ°Π»Π°ΡΡ Π² ΠΏΠ΅ΡΠΈΠΎΠ΄ 6 ΠΌΠ΅ΡΡΡΠ΅Π² ΠΈ ΡΠΎΡ
ΡΠ°Π½ΡΠ»Π°ΡΡ Π½Π° ΠΏΡΠΎΡΡΠΆΠ΅Π½ΠΈΠΈ Π³ΠΎΠ΄ΠΎΠ²ΠΎΠ³ΠΎ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ.ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΡΠ΅ ΡΠΈΡΡΠ΅ΠΌΡ ΡΠΈΡΠΊ-ΡΡΡΠ°ΡΠΈΡΠΈΠΊΠ°ΡΠΈΠΈ ΠΎΠ±Π»Π°Π΄Π°ΡΡ Π²ΡΡΠΎΠΊΠΎΠΉ ΠΏΡΠΎΠ³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π·Π½Π°ΡΠΈΠΌΠΎΡΡΡΡ; ΠΎΡΡΠΈΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΏΡΠ΅Π΄ΠΈΠΊΡΠΈΠ²Π½ΠΎΠΉ ΡΠΎΡΠ½ΠΎΡΡΡΡ, Ρ.Π΅. Ρ
ΠΎΡΠΎΡΠΎ ΠΏΡΠΎΠ³Π½ΠΎΠ·ΠΈΡΡΡΡ Π±Π»Π°Π³ΠΎΠΏΡΠΈΡΡΠ½ΡΠ΅ ΠΈΡΡ
ΠΎΠ΄Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
OKCBnST. ΠΠΎΠ΄Π΅Π»Ρ ΡΠΈΡΠΊΠ° GRACE ΠΎΠ±Π»Π°Π΄Π°Π΅Ρ ΠΌΠ°ΠΊΡΠΈΠΌΠ°Π»ΡΠ½ΠΎΠΉ ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡΡ ΠΏΡΠΈ ΠΏΡΠΎΠ³Π½ΠΎΠ·ΠΈΡΠΎΠ²Π°Π½ΠΈΠΈ ΡΠΌΠ΅ΡΡΠΈ ΠΈ ΡΠΌΠ΅ΡΡΠΈ ΠΈΠ»ΠΈ ΠΠ Π² ΠΏΠ΅ΡΠΈΠΎΠ΄ Π³ΠΎΡΠΏΠΈΡΠ°Π»ΠΈΠ·Π°ΡΠΈΠΈ ΠΈ Π½Π° ΠΏΠ΅ΡΠΈΠΎΠ΄ 6-ΠΌΠ΅ΡΡΡΠ½ΠΎΠ³ΠΎ ΠΈ Π³ΠΎΠ΄ΠΎΠ²ΠΎΠ³ΠΎ Π΄ΠΈΠ½Π°ΠΌΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ. Π¨ΠΊΠ°Π»Π° TIMI ΠΏΠΎΠΊΠ°Π·Π°Π»Π° Π½Π°ΠΈΠ±ΠΎΠ»ΡΡΠ΅Π΅ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ ΠΏΠΎΠ»ΠΎΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΏΡΠ΅Π΄ΡΠΊΠ°Π·ΡΡΡΠ΅ΠΉ ΡΠΎΡΠ½ΠΎΡΡΠΈ ΠΈ Π² ΠΏΠ΅ΡΠΈΠΎΠ΄ Π³ΠΎΡΠΏΠΈΡΠ°Π»ΠΈΠ·Π°ΡΠΈΠΈ, ΠΈ Π² ΠΏΠ΅ΡΠΈΠΎΠ΄ Π΄ΠΈΠ½Π°ΠΌΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ. Π‘ΠΈΡΡΠ΅ΠΌΠ° ΠΎΡΠ΅Π½ΠΊΠΈ ΡΠΈΡΠΊΠ° PURSUIT ΠΎΠ±Π»Π°Π΄Π°Π΅Ρ Π½Π°ΠΈΠ±ΠΎΠ»ΡΡΠ΅ΠΉ ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ½ΠΎΡΡΡΡ Π² ΠΏΡΠΎΠ³Π½ΠΎΠ·ΠΈΡΠΎΠ²Π°Π½ΠΈΠΈ Π³ΠΎΡΠΏΠΈΡΠ°Π»ΡΠ½ΡΡ
, 6-ΠΌΠ΅ΡΡΡΠ½ΡΡ
ΠΈ Π³ΠΎΠ΄ΠΎΠ²ΡΡ
ΠΈΡΡ
ΠΎΠ΄ΠΎΠ². ΠΡΡΠ΅ΡΠΊΠ°Π·Π°Π½Π½Π°Ρ ΡΠΈΡΡΠ΅ΠΌΠ° ΠΎΠ±Π»Π°Π΄Π°Π΅Ρ Π½Π°ΠΈΠ±ΠΎΠ»ΡΡΠ΅ΠΉ ΠΏΡΠ΅Π΄ΡΠΊΠ°Π·ΡΠ²Π°ΡΡΠ΅ΠΉ ΡΠΎΡΠ½ΠΎΡΡΡΡ Π² ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠΈ ΠΏΡΠΎΠ³Π½ΠΎΠ·Π° ΡΠΌΠ΅ΡΡΠΈ ΠΈ ΡΠΌΠ΅ΡΡΠΈ/ΠΈΠ½ΡΠ°ΡΠΊΡΠ° ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π° Π½Π° ΠΏΠ΅ΡΠΈΠΎΠ΄ Π³ΠΎΡΠΏΠΈΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΈ Π³ΠΎΠ΄ΠΎΠ²ΠΎΠ³ΠΎ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ
Influence of residual platelet reactivity on the development of repeated cardiovascular complications in patients with ACS without ST-segment elevation
The article is devoted to the characteristics of patients with acute coronary syndrome without ST elevation undergoing PCI. The influence of residual platelet reactivity on the development of repeated cardiovascular complications in these patients.Π‘ΡΠ°ΡΡΡ ΠΏΠΎΡΠ²ΡΡΠ΅Π½Π° Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠ΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΎΡΡΡΡΠΌ ΠΊΠΎΡΠΎΠ½Π°ΡΠ½ΡΠΌ ΡΠΈΠ½Π΄ΡΠΎΠΌΠΎΠΌ Π±Π΅Π· ΠΏΠΎΠ΄ΡΠ΅ΠΌΠ° ΡΠ΅Π³ΠΌΠ΅Π½ΡΠ° ST (OKCΠΠST), ΠΏΠΎΠ΄Π²Π΅ΡΠ³Π½ΡΡΡΡ
ΡΡΠ΅ΡΠΊΠΎΠΆΠ½ΠΎΠΌΡ ΠΊΠΎΡΠΎΠ½Π°ΡΠ½ΠΎΠΌΡ Π²ΠΌΠ΅ΡΠ°ΡΠ΅Π»ΡΡΡΠ²Ρ (Π§ΠΠ). ΠΠΎΠΊΠ°Π·Π°Π½ΠΎ Π²Π»ΠΈΡΠ½ΠΈΠ΅ ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΠΉ ΡΠ΅Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΡΡΠΎΠΌΠ±ΠΎΡΠΈΡΠΎΠ² Π½Π° ΡΠ°Π·Π²ΠΈΡΠΈΠ΅ ΠΏΠΎΠ²ΡΠΎΡΠ½ΡΡ
ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎ-ΡΠΎΡΡΠ΄ΠΈΡΡΡΡ
ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ Ρ Π΄Π°Π½Π½ΠΎΠΉ ΠΊΠ°ΡΠ΅Π³ΠΎΡΠΈΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ
The case of coronary artery disease in a patient with isolated dextrocardia
The article presents a clinical case of coronary artery disease in patient with dextrocardia. The article describes the clinical features and diagnosis of coronary heart disease associated with dextrocardia.Π ΡΡΠ°ΡΡΠ΅ ΠΏΡΠΈΠ²ΠΎΠ΄ΠΈΡΡΡ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΉ ΡΠ»ΡΡΠ°ΠΉ ΠΠΠ‘ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ° Ρ Π΄Π΅ΠΊΡΡΡΠΎΠΊΠ°ΡΠ΄ΠΈΠ΅ΠΉ. ΠΠΏΠΈΡΡΠ²Π°ΡΡΡΡ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠ΅ΡΠ΅Π½ΠΈΡ ΠΈ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ ΠΠΠ‘, ΡΠ²ΡΠ·Π°Π½Π½ΡΠ΅ Ρ Π΄Π΅ΠΊΡΡΡΠ°ΠΊΠ°ΡΠ΄ΠΈΠ΅ΠΉ
Risk assessment in acute coronary syndrome
Patients with acute coronary syndromes without ST-segment eievation are a heterogeneous group with different risk of early and late adverse events. Early risk stratification to determine the tactics of the patient. Interventional treatment in OKSBP ST significantly reduces mortality and myocardial infarction within 12 months, reduces the number of rehospitalization for the National Assembly, increases life expectancy. These circumstances determine the importance of risk stratification models that take into account a combination of several indicators. Experts GFCF ESC, ACC / AHA recommends several models. All scales have been developed for short and long-term prognosis: hospital and 6-month event GRACE: within 14 days and 12 months for the TIMI; 30 days and 12 months for PURSUIT.ΠΠΎΠ»ΡΠ½ΡΠ΅ ΠΎΡΡΡΡΠΌ ΠΊΠΎΡΠΎΠ½Π°ΡΠ½ΡΠΌ ΡΠΈΠ½Π΄ΡΠΎΠΌΠΎΠΌ Π±Π΅Π· ΠΏΠΎΠ΄ΡΠ΅ΠΌΠ° ΡΠ΅Π³ΠΌΠ΅Π½ΡΠ° ST ΡΠ²Π»ΡΡΡΡΡ Π³Π΅ΡΠ΅ΡΠΎΠ³Π΅Π½Π½ΠΎΠΉ Π³ΡΡΠΏΠΏΠΎΠΉ Ρ ΡΠ°Π·Π»ΠΈΡΠ½ΡΠΌ ΡΠΈΡΠΊΠΎΠΌ ΡΠ°Π½Π½ΠΈΡ
ΠΈ ΠΏΠΎΠ·Π΄Π½ΠΈΡ
Π½Π΅Π±Π»Π°Π³ΠΎΠΏΡΠΈΡΡΠ½ΡΡ
ΡΠΎΠ±ΡΡΠΈΠΉ. Π Π°Π½Π½ΡΡ ΡΡΡΠ°ΡΠΈΡΠΈΠΊΠ°ΡΠΈΡ ΡΠΈΡΠΊΠ° ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ΅Ρ ΠΎΠΏΡΠ΅Π΄Π΅Π»ΠΈΡΡ ΡΠ°ΠΊΡΠΈΠΊΡ Π²Π΅Π΄Π΅Π½ΠΈΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°. ΠΠ½ΡΠ΅ΡΠ²Π΅Π½ΡΠΈΠΎΠ½Π½Π°Ρ ΡΠ°ΠΊΡΠΈΠΊΠ° Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΠΠ‘ΠΠ ST Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎ ΡΠ½ΠΈΠΆΠ°Π΅Ρ ΡΠΌΠ΅ΡΡΠ½ΠΎΡΡΡ ΠΈ ΡΠ°ΡΡΠΎΡΡ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΠΠ Π² ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ 12 ΠΌΠ΅ΡΡΡΠ΅Π², ΡΠΏΠΎΡΠΎΠ±ΡΡΠ²ΡΠ΅Ρ ΡΠΌΠ΅Π½ΡΡΠ΅Π½ΠΈΡ ΡΠΈΡΠ»Π° ΠΏΠΎΠ²ΡΠΎΡΠ½ΡΡ
Π³ΠΎΡΠΏΠΈΡΠ°Π»ΠΈΠ·Π°ΡΠΈΠΉ ΠΏΠΎ ΠΏΠΎΠ²ΠΎΠ΄Ρ ΠΠ‘, ΡΠ²Π΅Π»ΠΈΡΠΈΠ²Π°Π΅Ρ ΠΏΡΠΎΠ΄ΠΎΠ»ΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡ ΠΆΠΈΠ·Π½ΠΈ. ΠΡΠΈ ΠΎΠ±ΡΡΠΎΡΡΠ΅Π»ΡΡΡΠ²Π° ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΡΡ Π²Π°ΠΆΠ½ΠΎΡΡΡ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΌΠΎΠ΄Π΅Π»Π΅ΠΉ ΡΡΡΠ°ΡΠΈΡΠΈΠΊΠ°ΡΠΈΠΈ ΡΠΈΡΠΊΠ°, ΠΊΠΎΡΠΎΡΡΠ΅ ΡΡΠΈΡΡΠ²Π°ΡΡ ΡΠΎΠ²ΠΎΠΊΡΠΏΠ½ΠΎΡΡΡ Π½Π΅ΡΠΊΠΎΠ»ΡΠΊΠΈΡ
ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ. ΠΠΊΡΠΏΠ΅ΡΡΠ°ΠΌΠΈ ΠΠΠΠ, ΠΠΠ, ΠΠΠ/ΠΠΠ‘ ΡΠ΅ΠΊΠΎΠΌΠ΅Π½Π΄ΠΎΠ²Π°Π½ΠΎ Π½Π΅ΡΠΊΠΎΠ»ΡΠΊΠΎ ΠΌΠΎΠ΄Π΅Π»Π΅ΠΉ. ΠΡΠ΅ ΡΠΊΠ°Π»Ρ Π±ΡΠ»ΠΈ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠ°Π½Ρ ΠΊΠ°ΠΊ Π΄Π»Ρ ΠΊΡΠ°ΡΠΊΠΎΡΡΠΎΡΠ½ΠΎΠ³ΠΎ, ΡΠ°ΠΊ ΠΈ Π΄Π»Ρ Π΄ΠΎΠ»Π³ΠΎΡΡΠΎΡΠ½ΠΎΠ³ΠΎ ΠΏΡΠΎΠ³Π½ΠΎΠ·Π°: Π³ΠΎΡΠΏΠΈΡΠ°Π»ΡΠ½ΡΡ
ΠΈ 6-ΠΌΠ΅ΡΡΡΠ½ΡΡ
ΡΠΎΠ±ΡΡΠΈΠΉ Π² GRACE; Π² ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ 14 Π΄Π½Π΅ΠΉ ΠΈ 12 ΠΌΠ΅ΡΡΡΠ΅Π² Π΄Π»Ρ TIMI; Π² ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ 30 Π΄Π½Π΅ΠΉ ΠΈ 12 ΠΌΠ΅ΡΡΡΠ΅Π² Π΄Π»Ρ PURSUIT
Influence of residual platelet reactivity on the development of repeated cardiovascular complications in patients with ACS without ST-segment elevation
The article is devoted to the characteristics of patients with acute coronary syndrome without ST elevation undergoing PCI. The influence of residual platelet reactivity on the development of repeated cardiovascular complications in these patients.Π‘ΡΠ°ΡΡΡ ΠΏΠΎΡΠ²ΡΡΠ΅Π½Π° Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠ΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΎΡΡΡΡΠΌ ΠΊΠΎΡΠΎΠ½Π°ΡΠ½ΡΠΌ ΡΠΈΠ½Π΄ΡΠΎΠΌΠΎΠΌ Π±Π΅Π· ΠΏΠΎΠ΄ΡΠ΅ΠΌΠ° ΡΠ΅Π³ΠΌΠ΅Π½ΡΠ° ST (ΠΠΠ‘ΠΠΠΠ’), ΠΏΠΎΠ΄Π²Π΅ΡΠ³Π½ΡΡΡΡ
ΡΡΠ΅ΡΠΊΠΎΠΆΠ½ΠΎΠΌΡ ΠΊΠΎΡΠΎΠ½Π°ΡΠ½ΠΎΠΌΡ Π²ΠΌΠ΅ΡΠ°ΡΠ΅Π»ΡΡΡΠ²Ρ (Π§ΠΠ). ΠΠΎΠΊΠ°Π·Π°Π½ΠΎ Π²Π»ΠΈΡΠ½ΠΈΠ΅ ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΠΉ ΡΠ΅Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΡΡΠΎΠΌΠ±ΠΎΡΠΈΡΠΎΠ² Π½Π° ΡΠ°Π·Π²ΠΈΡΠΈΠ΅ ΠΏΠΎΠ²ΡΠΎΡΠ½ΡΡ
ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎ-ΡΠΎΡΡΠ΄ΠΈΡΡΡΡ
ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ Ρ Π΄Π°Π½Π½ΠΎΠΉ ΠΊΠ°ΡΠ΅Π³ΠΎΡΠΈΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ
Relationship of depressive disorders with hypertension, its control and other metabolic risk factors in the Tyumen Oblast population of men and women. Data from the study βEpidemiology of Cardiovascular Diseases and their Risk Factors in Regions of Russian Federationβ (ESSE-RF)
Aim. To study the association between depression and metabolic cardiovascular risk factors, hypertension (HTN) and its control in a random sample of Tyumen Oblast population of men and women aged 25-64 years.Material and methods. The study object was a random sample of the population of the Tyumen and the Tyumen Oblast aged 25-64 years, examined as part of the ESSE-RF epidemiological study. The study included 1658 participants. Among them, 30,3% (n=503) were men, while 69,7% (n=1155) β women. Mean age was 48,9Β±11,4 years. The prevalence of metabolic risk factors (hyperlipidemia, carbohydrate metabolism disorder, obesity), hypertension and the likelihood of its control in men and women with different levels of depressive disorders diagnosed using the HADS scale were assessed.Results. Compared with participants without depression, persons with psychological disorders were significantly more likely to have HTN (55,5% vs 47,6%, p<0,01), elevated levels of total cholesterol (TC) (63,9% vs 54,0%, p<0,01) and low-density lipoproteins (LDL) (66,7% vs 60,3%, p<0,05), carbohydrate metabolism disorders (8,3% vs 5,2% p<0,05), obesity (49,2% vs 37,7%, p<0,01). Significantly more often hypertensive subjects without depression took antihypertensive drugs effectively (odds ratio (OR) β 1,747, 95% confidence interval (CI), 1,001-3,053) and controlled blood pressure (OR β 1,533, 95% CI, 1,05-2,36). There was no association between the use of antihypertensives and the level of depressive disorders. Among women with depression (HADS>7), dyslipidemia (65,5% vs 57,4% for TC, p<0,05; 71,0% vs 62,9% for LDL, p<0,05), carbohydrate metabolism disorders (10,1% vs 5,2%, p<0,01), obesity (53,3% vs 43,2%, p<0,01), HTN (60,6% vs 45,6%, p<0,01) were more common. Men with clinical depression were more likely to have HTN (69,0% vs 47,7%, p<0,05), with a high level of depression β hyperlipidemia (58,9% vs 46,7% for TC, p<0,05; 67,1% vs 53,9% for LDL, p<0,05). Women with elevated depression levels were less likely to take antihypertensive drugs (30% vs 49,4%, p<0,01) and control hypertension (13,8% vs 21,2%, p<0,05).Conclusion. The data obtained confirm the association of depressive disorders with metabolic risk factors and the likelihood of HTN control, which is especially significant among women
ERA OF NEW ANTICOAGULANTS IN THE TREATMENT OF NON-VALVULAR ATRIAL FIBRILLATION: PROSPECTS AND CHALLENGES
Studies data on new anticoagulants, direct oral thrombin inhibitor (dabigatran) and direct inhibitors of coagulation factor Xa (rivaroxaban, apixaban), in the treatment of nonvalvular atrial fibrillation are presented. Effects of these drugs on cardiovascular events in atrial fibrillation are analyzed based on the results of various studies. Prospects for further research are discussed.</p
Effect of statins on the risk of new cases of diabetes
The recent literature demonstrates an increase in the risk of new cases of diabetes in patients receiving statins. The review examines recent studies devoted to the problem, and possible mechanisms of disorders of glucose metabolism against a background of statin therapy. Target levels of atherogenic lipids in patients with diabetes and metabolic syndrome are analyzed